deltatrials
Terminated PHASE3 INTERVENTIONAL 4-arm NCT02660359

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis

Sponsor: Ipsen

Updated 23 times since 2017 Last updated: Sep 15, 2022 Started: Jul 8, 2016 Primary completion: Nov 9, 2018 Completion: Jul 4, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment of patients

A PHASE3 clinical study on Overactive Bladder and Urinary Incontinence, this trial is terminated or withdrawn. The trial is conducted by Ipsen and has accumulated 23 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~May 2018 · 4 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Aug 2019 · 6 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

23 versions recorded
  1. Nov 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Terminated PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  5. Sep 2022 — Jul 2024 [monthly]

    Terminated PHASE3

Show 18 earlier versions
  1. Dec 2021 — Sep 2022 [monthly]

    Terminated PHASE3

  2. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Sep 2021 [monthly]

    Terminated PHASE3

  4. Dec 2019 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Oct 2019 — Dec 2019 [monthly]

    Terminated PHASE3

    Status: CompletedTerminated

  6. Aug 2019 — Oct 2019 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  7. Feb 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  9. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  10. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  11. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  12. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  13. Jan 2018 — May 2018 [monthly]

    Recruiting PHASE3

  14. Nov 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  15. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  16. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  17. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ipsen
Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .